Galectin Therapeutic (GALT) Stock Price, Quote & News

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and he...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 620 3186

Website: galectintherapeutics.com

Address:

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States

ThomasLD Apr. 8 at 2:48 PM

$GALT FDA will likely try to bring Belapectin to the US market in the future. The question is that what will be on the label? Limited label OR better label for a very high unmet need?

1 · Reply

Nelly0414 Apr. 8 at 1:51 PM

$GALT The people shorting GALT do so with impunity , the door is open feel free , just a hint of talks in progress , a whisper of impending partnership , a little leak , is it to much to ask , or is this creative type of management scorened in our Stuffy rigid boring Boardroom

0 · Reply

maybeme54 Apr. 8 at 1:46 PM

$GALT even if this closes green. This little pump in the market aint going to last very long. Decisions will need to be made...

0 · Reply

Indibviduate1 Apr. 8 at 1:44 PM

$GALT cheap shares. May be last chance

1 · Reply

Wardstock Apr. 8 at 1:34 PM

$GALT picked up another 250 shares in the drop..To the moon

0 · Reply

ThomasLD Apr. 8 at 1:05 PM

$GALT Out of 53, I like Ben H., Andreas W., Naim A., Morten K. (CEO of Nordic Bioscience).

0 · Reply

Indibviduate1 Apr. 8 at 9:48 AM

$GALT it’s these selloffs for reasons of war that offer the most wonderful opportunities to buy these shares because they have nothing to do with the drug or the company or the data. Shorts are trapped here and need to sell it down. Just another reason the price doesn’t reflect the value.

1 · Reply

Indibviduate1 Apr. 8 at 6:00 AM

$GALT

1 · Reply

Indibviduate1 Apr. 8 at 3:34 AM

$GALT

1 · Reply

Indibviduate1 Apr. 8 at 3:31 AM

$GALT

1 · Reply

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Dec 29, 2025, 9:54 PM EST - 3 months ago

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm

Nov 14, 2025, 8:00 AM EST - 5 months ago

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

Sep 2, 2025, 8:00 AM EDT - 7 months ago

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

May 12, 2025, 8:00 AM EDT - 11 months ago

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Jan 10, 2025, 8:00 AM EST - 1 year ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Dec 20, 2024, 10:29 AM EST - 1 year ago

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Dec 20, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Nov 18, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Nov 14, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

May 15, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Dec 7, 2023, 6:00 AM EST - 2 years ago

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Nov 13, 2023, 8:45 AM EST - 2 years ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Sep 13, 2023, 5:22 PM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Sep 7, 2023, 12:00 PM EDT - 2 years ago

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

May 15, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

Apr 27, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

Mar 30, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 16, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Jan 24, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Jan 5, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Nov 28, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Nov 14, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Nov 1, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

Oct 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming Conferences

Oct 12, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

Aug 15, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

Jul 26, 2022, 8:00 AM EDT - 4 years ago

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

ThomasLD Apr. 8 at 2:48 PM

$GALT FDA will likely try to bring Belapectin to the US market in the future. The question is that what will be on the label? Limited label OR better label for a very high unmet need?

1 · Reply

Nelly0414 Apr. 8 at 1:51 PM

0 · Reply

maybeme54 Apr. 8 at 1:46 PM

$GALT even if this closes green. This little pump in the market aint going to last very long. Decisions will need to be made...

0 · Reply

Indibviduate1 Apr. 8 at 1:44 PM

$GALT cheap shares. May be last chance

1 · Reply

Wardstock Apr. 8 at 1:34 PM

$GALT picked up another 250 shares in the drop..To the moon

0 · Reply

ThomasLD Apr. 8 at 1:05 PM

$GALT Out of 53, I like Ben H., Andreas W., Naim A., Morten K. (CEO of Nordic Bioscience).

0 · Reply

Indibviduate1 Apr. 8 at 9:48 AM

1 · Reply

Indibviduate1 Apr. 8 at 6:00 AM

$GALT

1 · Reply

Indibviduate1 Apr. 8 at 3:34 AM

$GALT

1 · Reply

Indibviduate1 Apr. 8 at 3:31 AM

$GALT

1 · Reply

Indibviduate1 Apr. 8 at 3:28 AM

$GALT

0 · Reply

Indibviduate1 Apr. 8 at 3:27 AM

$GALT oh the shorts are so happy with their work.

1 · Reply

immashortdis Apr. 8 at 3:17 AM

$GALT lol wow indeed

0 · Reply

johnhankowitz Apr. 8 at 3:06 AM

$GALT Adding more tomorrow on any dip if it happens. News on the way

0 · Reply

ThomasLD Apr. 8 at 1:53 AM

$GALT GALT may offer up to $32.5 mln common stock under ATM agreement with H.C. Wainwright - SEC filing. So, I am wondering if lately H.C. Wainwright did an ATM at higher prices in order to have extra cash $$$$$$$$$ for better negotiation / future ph3 study with a partner?

1 · Reply

Indibviduate1 Apr. 8 at 1:45 AM

$GALT the science is groundbreaking. The need is urgent and unmet and addresses a massive clinical and economic burden but the company has always been hopeless at communications and this allows the shorts to drive the share price to their benefit whenever macro news creates a risk off market. But we haven’t invested for short term gains. We are waiting for the day this is sold for many billions. In the meantime the shorts will play their games. And post their fud.

1 · Reply

jrtrad Apr. 8 at 12:25 AM

$GALT Now that we have a 2 week cease fire and open strait in Iran, wonder if we will see a bounce back in this stock after the way it traded today.

1 · Reply

D_Coral Apr. 7 at 11:51 PM

$GALT Market cap comparison of biotechs that have a MASH drug in phase 3 (see image). When GALT finalizes the phase 3 registration trial details, there is compelling reason to believe it can quickly rise to a similar market cap as its peers, at least 10x the current price.

0 · Reply

Nelly0414 Apr. 7 at 11:36 PM

$GALT We need a sense of urgency but we get Silence……we are a sitting in a box languishing in the storeroom waiting to be discovered , the longer this goes on the harder it gets , even our great scientific achievements start to pale …..headwinds are growing stronger , patients who could be helped are dieing. WHAT ARE WE WAITING FOR ?

0 · Reply

ThomasLD Apr. 7 at 10:51 PM

$GALT The drug works and safe! FDA is very smart and they will know what to do. See below for manipulating. Be patient!

0 · Reply

Scarlivertriumphant Apr. 7 at 10:44 PM

$GALT If you longs want a pickme up, just go on to Dr. Jamil's Linkedin page and see his post (with accompanying photos) on the recent Baveno conference. Then look at the 53 people (as of right now) who have given him the thumbs up on that post. Draw your own conclusions.

0 · Reply

kookiemonsteryum Apr. 7 at 10:38 PM

$GALT Recent discussion at Baveno VIII highlights increasing recognition of varices as a clinically meaningful endpoint in cirrhosis trials. That’s important because belapectin has already demonstrated reduction in new varices formation. So the question isn’t whether the drug shows activity — it’s whether the evolving trial design and endpoint selection now align with where the drug is strongest. Is this a fair point or it doesn't matter and we going to zero

2 · Reply

Market Cap	168.52M
Revenue (ttm)	0.00
Net Income (ttm)	-30.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	737,500
Avg Vol	317,384
Day's Range	N/A - N/A
Shares Out	65.83M
Stochastic %K	1%
Beta	1.03
Analysts	Sell
Price Target	$11.00